Company intelligence / Profile preview

Biokinesis

Paris, France

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Biokinesis was a French oncology biotech developing a first-in-class KIF20A inhibitor targeting the Golgi apparatus (DIACC2010), with impressive preclinical data in acute myeloid leukemia and lymphoma before being acquired and absorbed by Diaccurate in early December 2020.[1][5]

Therapeutic areas: HematologyOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Truffle Capital (lead investor in both Biokinesis and Diaccurate, instrumental in merger)[1]

Beyond the preview

Go deeper on Biokinesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biokinesis.

Explore the full profile